Management

With over 35 years of experience in the life sciences industry, Mr. Giancola brings a wealth of knowledge and a proven track record of business development and strategic growth success to this role. He is passionate about neuromodulation technology and its powerful ability to transform lives.

 

As Owner and Managing Director of Otomed Consulting, LLC, Mr. Giancola has advised global leaders, emerging companies, venture capital and investment firms in the life sciences space on business development and operational systems of neuromodulation devices, including novel tinnitus treatments, hearing implants and innovative approaches for other neurological disorders. 

 

At Cochlear Americas, his team built the Latin American business, growing revenue by 30% year-over-year and establishing Latin America as a key component of Cochlear’s global strategy. He then joined Neuromonics, Inc. as CEO (later acquired by SoundVida) and bone conduction hearing pioneer Sophono (acquired by Medtronic). As Executive Vice President of the Americas/EMEA at Nurotron Biotechnology, Inc., Mr. Giancola drove significant growth by heading all commercial, clinical, research, regulatory, education and training activities for the Americas, Europe, the Middle East and Africa. His strategic initiatives resulted in a fivefold increase in sales in Latin America and EMEA in these diverse global markets.

 

Mr. Giancola holds an MBA from Syracuse University and a BA from Hobart College. Outside of work, he enjoys cycling, skiing, golfing and lacrosse. His commitment to professional and community involvement is evident through his roles on various boards and committees.

Weaver Gaines has over 40 years of entrepreneurial, management, and legal experience, including over 25 years as a founder, fund-raiser, and manager of start-up life science companies. Most recently, he was a co-founder and CEO of OBMedical Company, a medical device company that developed and received FDA clearance for an electronic maternal fetal monitor, which was acquired by Philips Healthcare in 2018.

​

From 2008 to 2017, Gaines was Chairman of the Board of Nanotherapeutics, Inc. (now Ology Bioservices, Inc.), a specialty pharma company and manufacturer of a bone extender cleared by the FDA. Prior that that, Gaines founded Ixion  Biotechnology, a Florida-based, clinical-stage biotechnology company that developed stem cell and probiotic therapies focused on treatment of metabolic disorders. Ixion’s probiotic technology was acquired by QMed AB in 2007.

​

Gaines received a BA from Dartmouth College and a JD from the University of Virginia School of Law and was an Infantry officer who served in Vietnam from 1969-70, with a final rank of Captain.

Neil Euliano has spent the past 20 years leading teams developing medical devices and technology. He is the chief designer and manager of the FDA cleared Philips Healthcare VentAssist team that developed intelligent decision support software for ventilated patients. He holds over 40 U.S. patents and has ten more pending. In addition, he has a long history in managing multi-disciplinary medical development teams and 19 years of experience managing R&D grants, including over $12M in industry and government funded research.

 

His commercialization and entrepreneurial experience includes being the cofounder of two companies, both of which led to FDA clearance, commercial sales, and acquisition. He served as Chairman of the Board and CTO of OBMedical during their acquisition by Philips Healthcare. He has been involved in the successful FDA clearance of more than 6 medical devices. Euliano is currently a Senior Science Advisor to etectRX, a Senior Advisor to Philips Healthcare, and a Courtesy Assistant Professor at the Department of Anesthesiology at the University of Florida.

​

Euliano holds a PhD in Signal Processing and Electrical Engineering, an MSEE in Electrical Engineering, and a BSE in Computer Science all from the University of Florida.

A serial entrepreneur, with 30 years progressive corporate finance and operations experience, Ramsey has played a key role in raising over $100 million, including several successful IPOs. Most recently, she has been providing executive consulting services to medical device start-ups as founder and president of Bio/Med CXO. As co-founder and Chief Financial Officer for OBMedical Company, she played a key role in forwarding a ground-breaking wireless fetal/maternal monitor for use in labor and delivery departments, raising over $10M in private equity, leading to a successful acquisition by Philips Healthcare. Prior to that, she was key to successful mergers and IPOs in the biotech, med device and high-tech arenas.

 

Ramsey holds a BSAc from the Fisher School of Accounting at the University of Florida.

John Abernethy, MD, is the Chief Medical Officer at Serodopa Therapeutics. He also serves as the Medical Director with Meridian Behavioral Healthcare where he is responsible for OTP, detox unit and long-term residential; working with patients with addiction in a variety of settings with an emphasis on opioid addiction. In these roles, he works with many patients seeking relief from PTSD. Previously, he was the Medical Director at. Ology Bioservices (previously Nanotherapeutics, Inc.) and served on the faculty at University of Florida College of Medicine in Gainesville, FL.

 

Dr. Abernethy is a Major in the U.S.  Army Reserve Medical Corps. He is a graduate of the University of Florida Medical School.

Josh Kelly was introduced to the Company during his capstone course at the University of Florida. He was selected by his peers to lead the Long Term Strategy Team for Evren during his final semester. Following graduation, he was offered a full time role with the Company as an Associate Product Manager in 2021. He was appointed Corporate Secretary later that year. Josh's role with the Company expanded to include digital marketing, corporate communications, R&D, and earpiece manufacturing. He was appointed Head of Marketing in 2022, then Director of Operations in 2023, his current role. 

 

He previously was a consultant with Asymetric Solutions, and a Deputy State Director - Wisconsin for In Field Strategies. He graduated with a degree in public relations from the University of Florida in 2019.

Sahil Raje joined Evren Technologies as a business analyst in 2023. In his prior roles, Sahil participated as a graduate equity analyst of the Reese Fund portfolio at Indiana University. He` analyzed various securities in the financial industry and evaluated firm financials and growth factors to assess the viability of their business plans. During his internship, Sahil conducted data analysis for budgeting and financial planning purposes while supporting leadership in completing standard cost templates. At Florida State University, Sahil worked as a student equity researcher, collaborating with team members to trade securities in a $4.35M actively managed fund.

​

Sahil received a BS in Finance and Management Information Systems from Florida

State University and an MS in Finance from Indiana University.